Question 344 of 433
Clinics offer “senolytic protocols” and mail-order rapamycin. Should I?
The short answer
Not outside a study, for the reasons in Part 18. The largest human trials so far missed their main goals.
The dasatinib-and-quercetin combination failed to improve bone turnover overall in its first randomized trial. Rapamycin did not reduce belly fat in the PEARL trial. Both may yet prove useful. Today they are promises, not proof. Dasatinib is a leukemia drug with serious side effects; it has no business in a wellness package.
“This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship.” From the book’s medical disclaimer. Full disclaimer
SMALL / NEGATIVE HUMAN TRIALS — Healthy-aging senolytic or rapamycin protocols: no established disease-prevention benefit.Evidence grade (draft mapping)BLimited or small human studiesPart 22, Q344 · Part sources
From Longevity Unmasked by Afshine Ash Emrani, MD, FACC. Medical disclaimer. This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship. Nothing here is meant to diagnose, treat, cure, or prevent any disease. Medicine is personal: a test, drug, supplement, or exercise plan that helps one person can harm another. Do not start, stop, or change any medication or treatment because of something you read in these pages. Talk with a licensed clinician who knows your history first. If you think you are having a medical emergency, call 911. The author disclaims responsibility for any loss or harm arising from use of the information in this book.